Andrew Miclot, the former President and CEO of Ascension Orthopedics and prior to that, a senior exec at Orthofix, Symmetry Medical, DePuy, and Zimmer, is the new Senior Vice President and General Manager of ArthroCare’s Ear, Nose and Throat business.
Andrew Miclot Joins ArthroCare
1 min read Premium comments
Andrew is now responsible for worldwide sales of ArthroCare’s Coblation tonsillectomy and adenoidectomy products. ArthroCare also markets a version of its coblation technology for turbinate (the long, narrow and curled bone shelf which protrudes into the breathing passage of the nose) reduction. Large, swollen turbinates can block or restrict breathing through the nose. Probably the largest market for coblation treatment of the turbinate is to treat severe snoring.
In total, Mr. Miclot has more than 25 years of executive management experience within the medical device industry. He spent most of that time (13 years) at Symmetry Medical, including stents as Senior Vice President and Investor Relations Officer.
Mr. Miclot earned a Bachelor degree in Speech and Hearing Sciences and a MA in Audiology from Indiana University. In addition, he earned a MBA from the Lake Forest Graduate School of Management.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.